Veru Inc. - Common Stock (NQ:VERU)

2.550 +0.040 (+1.59%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veru Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Recap: Veru Q1 Earnings ↗

February 09, 2022

Veru (NASDAQ:VERU) reported its Q1 earnings results on Wednesday, February 9, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 9, 2022 ↗

February 09, 2022

Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.

Via Benzinga

5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet ↗

February 04, 2022

Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit.

Via InvestorPlace

Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19 ↗

January 31, 2022

The FDA has granted Fast Track designation to Veru Inc's (NASDAQ:

Via Benzinga

Promising Developments in Breast Cancer Treatments Ahead in 2022

January 12, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...

Via FinancialNewsMedia

Veru Posts Mixed Q4 Results ↗

December 02, 2021

Veru Inc (NASDAQ: VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million. FC2...

Via Benzinga

Veru: Q4 Earnings Insights ↗

December 02, 2021

Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Veru...

Via Benzinga

Veru: Q3 Earnings Insights ↗

August 12, 2021

Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to...

Via Benzinga

48 Biggest Movers From Yesterday ↗

January 12, 2022

Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT...

Via Benzinga

9 Consumer Staples Stocks Moving In Tuesday's Intraday Session ↗

January 11, 2022

Gainers Veru (NASDAQ:VERU) shares moved upwards by 21.5% to $6.49 during Tuesday's regular session. As of 12:31 EST, this security is trading at a volume of 7.0...

Via Benzinga

30 Stocks Moving In Tuesday's Mid-Day Session ↗

January 11, 2022

Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year....

Via Benzinga

Earnings Outlook For Veru ↗

August 11, 2021

On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And...

Via Benzinga

Why Jim Cramer Likes Grab Holdings ↗

January 11, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ:

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 06, 2022

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

How Good Are Veru's Earnings? | Return On Capital Employed ↗

December 03, 2021

According to Benzinga Pro data, during Q4, Veru (NASDAQ:VERU) posted sales of $15.65 million. Earnings were up 34.84%, but Veru still reported an overall loss of $1.87 million. In...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance ↗

December 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-...

Via Benzinga

Earnings Scheduled For December 2, 2021 ↗

December 02, 2021

Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report earnings for its third quarter. • LightInTheBox Holding (NYSE:LITB) is...

Via Benzinga

Earnings Outlook For Veru ↗

December 01, 2021

Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

10 Consumer Staples Stocks Moving In Monday's After-Market Session ↗

November 22, 2021

Gainers 111 (NASDAQ:YI) shares rose 3.81% to $4.35 during Monday's after-market session. The market value of their outstanding shares is at $360.4 million. The company's, Q3...

Via Benzinga

Cramer Gives His Take On Change Healthcare, Veru And More ↗

November 11, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Change Healthcare Inc. (NASDAQ: CHNG) is a good, steady firm. Cramer said with Veru Inc. (NASDAQ: VERU)...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

Why Veru Stock Vaulted Higher Today ↗

September 02, 2021

An analyst raised his price target for the stock.

Via The Motley Fool

Why Veru Stock Blasted Higher on Friday ↗

August 27, 2021

An analyst argues that the company has far more value than many realize.

Via The Motley Fool

Veru Stock Gains After Q3 Result Tops Estimates ↗

August 12, 2021

Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2...

Via Benzinga

Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients ↗

June 07, 2021

Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent,...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Earnings Scheduled For August 12, 2021 ↗

August 12, 2021

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.